Traditional　photodynamic　therapy　(PDT)　requires　external　light　excitation　to　produce　reactive　oxygen　species　(ROSs)　for　the　treatment　of　tumors.　Due　to　problems　of　light　penetration,　traditional　PDT　is　limited　by　the　location　and　depth　of　the　tumor.　In　this　study,　we　rationally　designed　and　constructed　a　novel　strategy　to　amplify　the　therapeutic　effect　of　PDT.　We　prepared　a　chlorin-lipid　nanovesicle　based　on　the　conjugates　of　chlorin　e6　(Ce　6)　and　phospholipids,　with　the　surface　conjugating　the　aptamer　for　lung　cancer　targeting,　GLT21.T.I-131-labeled　bovine　serum　albumin　(I-131-BSA)　was　loaded　into　the　chlorin-lipid　nanovesicle　cavity　(I-131-BSA@LCN-Apt).I-131　not　only　plays　a　role　in　radiotherapy,　but　its　Cerenkov　radiation　(CR),　as　an　internal　light　source,　can　also　stimulate　Ce6　to　produce　ROSs　without　external　light　excitation.　Thein　vitroandin　vivotherapeutic　effects　in　subcutaneous　lung　tumor　models　and　orthotopic　lung　tumor　models　indicated　that(131)I-BSA@LCN-Apt　produced　a　powerful　anti-tumor　effect　through　synergistic　radiotherapy　and　CR-PDT,　which　almost　caused　complete　tumor　growth　regression.　After　treatment,　the　survival　time　of　the　mice　was　significantly　prolonged.　During　the　treatment,　no　obvious　side　effects　were　found　by　histopathology　of　important　organs,　hematology　and　biochemistry　analysis　except　the　decrease　of　the　white　blood　cell　count　(WBC).　The　study　provides　a　major　tool　for　deep-seated　tumors　to　obtain　amplified　therapeutic　effects　by　synergistic　radiotherapy　and　CR-PDT　without　the　use　of　any　external　light　source.